Washington, DC 20549



Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2024


(Exact name of registrant as specified in its charter)






(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)

910 Clopper Road, Suite 201S

Gaithersburg, Maryland


(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number including area code: (240) 654-1450

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share


The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 25, 2024, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Andrew Shutterly as acting Chief Financial Officer, “principal financial officer” and “principal accounting officer,” effective immediately following the unexpected death of Richard Eisenstadt, the Company’s Chief Financial Officer.

Mr. Shutterly, age 36, has served as the Corporate Controller of the Company since February 2023. Mr. Shutterly joined the Company in October 2020 as Assistant Controller. Prior to joining the Company, Mr. Shutterly served as Accounting Supervisor at Meso Scale Diagnostics LLC, a biotechnology company, from September 2017 to October 2020 and as an Audit Manager at Deloitte from October 2014 to September 2017. Mr. Shutterly received both a B.S. and M.S. in Accounting from Virginia Tech.

There are no family relationships between Mr. Shutterly and any director or executive officer of the Company, and the Company has not entered into any transactions with Mr. Shutterly that are reportable pursuant to Item 404(a) of Regulation S-K.

The Company will enter into an indemnification agreement with Mr. Shutterly in connection with the foregoing, which will be in substantially the same form as that entered into with the other executive officers of the Company filed as Exhibit 10.24 to the Company's annual report on Form 10-K.

Item 7.01 Regulation

On June 26, 2024, the Company issued a press release, the entire text of which is attached as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits






Press Release of Altimmune, Inc. dated June 26, 2024


Cover Page Interactive Data File (embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




/s/ Vipin K. Garg


Name: Vipin K. Garg


Title: President, Chief Executive Officer

Dated: June 26, 2024


Exhibit 99.1

Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt

GAITHERSBURG, MD – June 26, 2024 – Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Company’s Chief Financial Officer, passed away unexpectedly on Monday, June 24, 2024.

“We are all shocked and saddened by Rich’s passing. On behalf of everyone at Altimmune, I extend our heartfelt condolences to his family during this difficult time,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “Rich was not only a brilliant and dedicated leader, but a close friend who brought a sense of wit and joy to our workplace that will be dearly missed by all who had the privilege of working with him.  His unique blend of hard work and humor, along with his immeasurable contributions to our Company will continue to inspire us.”

Mr. Eisenstadt’s duties have been assumed and are being performed by Altimmune’s finance and accounting team until his replacement is named.  The company has initiated a search for his replacement.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:

Vipin Garg

President and Chief Executive Officer

Phone: 240-654-1450


Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403


Julia Weilman

Burns McClellan

Phone: 646-732-4443



Media Contact:

Danielle Cantey

Inizio Evoke, Biotech

Phone: 619-826-4657